| 姓名 | 職稱 | 持有股份 | 代表法人 |
|---|---|---|---|
| Chen,De-Li | Chairman | 3.11% | |
| Wang,Su-Qi | Director | 30.24% | Center Laboratories, Inc. |
| Lin,Rong-Jin | Director | 0.00% | |
| Vacancy | Director | ||
| Vacancy | Director | ||
| Ceng,Hou | Independent Director | 0.00% | |
| Zhang,Xuan-Hao | Independent Director | 0.00% | |
| Jian,Shao-Feng | Independent Director | 0.00% | |
| Zhang,Feng-Yi | Independent Director | 0.00% |
Change Person in Charge to Chen,De-Li
2022/08/17
Change Capital to 2,500,000,000
2022/07/18
Change Person in Charge to Lin,Rong-Jin
2022/07/18
Change Person in Charge to Yu,Cheng-Sheng-Ji-Tou-Zi-Gu-Fen-You-Xian-Gong-Si
2022/01/12
Change Capital to 1,500,000,000
2019/05/28
Change Capital to 1,000,000,000
2018/10/08
Change Company Name to BioGend Therapeutics Co., Ltd.
2017/02/20
Change Person in Charge to Chen,De-Li
2017/02/20
Change Company Name to None
2016/07/07
Change Person in Charge to
2016/07/07
下載完整報告查看完整數據
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Operating income | 47,472 | 167,648 | 109,908 |
| Operating cost | 11,003 | 37,140 | 20,290 |
| Profit (loss) of initial recognition of biological asset and agricultural products | - | - | - |
| Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - | - | - |
| Operating gross profit (loss) | 36,469 | 130,508 | 89,618 |
| Unrealized profit (loss) on sales of goods | - | - | - |
| Realized profit (loss) on sales of goods | - | - | - |
| Operating gross profit (loss), net | 36,469 | 130,508 | 89,618 |
| Operating expenses | 77,460 | 252,768 | 266,159 |
| Other gain (loss), net | - | - | - |
| Operating profit (loss) | -40,991 | -122,260 | -176,541 |
| Non-operating income and expenses | 2,517 | -5,988 | 7,319 |
| Net profit (loss) before tax | -38,474 | -128,248 | -169,222 |
| Income tax expense (benefits) | -2,099 | -8,308 | -8,304 |
| Net profit (loss) of ongoing business for the current period | -36,375 | -119,940 | -160,918 |
| Profit (loss) of closed units | - | - | - |
| Profit (loss) of non-jointly controlled equity before merger | - | - | - |
| Net profit (loss) for the current period | -36,375 | -119,940 | -160,918 |
| Other comprehensive profit (loss), net | 1,136 | 6,045 | -13,581 |
| Comprehensive net profit and loss of non-jointly controlled equity before merger | - | - | - |
| Total comprehensive profit and loss for the current period | -35,239 | -113,895 | -174,499 |
| Net profit (loss) attributable to owners of parent company | -33,286 | -116,472 | -156,325 |
| Net profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Net profit (loss) attributable to non-controlling interests | -3,089 | -3,468 | -4,593 |
| Comprehensive profit (loss) attributable to owners of parent company | -32,448 | -126,928 | -161,905 |
| Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Comprehensive profit (loss) attributable to non-controlling interests | -2,791 | 13,033 | -12,594 |
| Basic earnings per share (yuan) | 0 | 0 | -1 |
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Net cash inflow (outflow) from operating activities | -32,587 | -98,908 | -138,720 |
| Net cash inflows (outflows) from investing activities | -50,728 | -8,199 | -89,636 |
| Net cash inflow (outflow) from financing activities | -923 | -3,641 | 396,417 |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | 571 | -739 | -1,194 |
| Increase (decrease) in cash and cash equivalents in the current period | -83,667 | -111,487 | 166,867 |
| Beginning balance of cash and cash equivalents | 219,023 | 330,510 | 163,643 |
| Ending balance of cash and cash equivalents | 135,356 | 219,023 | 330,510 |
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Current asset | 687,008 | 717,702 | 801,177 |
| Non-current asset | 183,029 | 195,000 | 249,304 |
| Total asset | 870,037 | 912,702 | 1,050,481 |
| Current liability | 27,347 | 33,232 | 46,251 |
| Non-current liability | 30,039 | 32,961 | 47,463 |
| Total liability | 57,386 | 66,193 | 93,714 |
| share capital | 1,242,560 | 1,242,560 | 1,230,760 |
| Equity - secruity token | - | - | - |
| capital reserve | -153 | -153 | 0 |
| retained earning | -431,603 | -398,317 | -281,845 |
| Other equity | -24,205 | -26,424 | -7,958 |
| Treasury stock | - | - | - |
| Total equity attributable to owners of parent company | 786,599 | 817,666 | 940,957 |
| Equity attributable to former owner of business combination under common control | - | - | - |
| Equity attributable to non-controlling interest before business merger under common control | - | - | - |
| Non-controlling interests | 26,052 | 28,843 | 15,810 |
| Total Equity | 812,651 | 846,509 | 956,767 |
| Share capital awaiting retirement (unit: share) | 0 | 0 | 0 |
| Issued shares of advance equity (unit: shares) | 0 | 0 | 0 |
| Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 0 | 0 | 0 |
| Net asset value per share | 6 | 6 | 7 |
| 標案名稱 | 機關名稱 | 決標日期 | 決標金額 | 是否得標 |
|---|---|---|---|---|
| 骨科部用醫療特材乙項 | 高雄榮民總醫院 | 113/06/26 | 190000.0 | 是 |
| 骨科部一次性自體軟骨修補系統計 1 項 | 高雄榮民總醫院 | 113/06/04 | 190000.0 | 是 |
| 113年第1-8批臨購衛材4項採購案 | 衛生福利部豐原醫院 | 113/04/02 | 4290000.0 | 是 |
| 藥品一批單價合約 | 國立臺灣大學醫學院附設醫院 | 113/03/28 | 是 | |
| 「骨材等10項」2年期單價開口契約 | 臺中榮民總醫院 | 113/01/03 | 10850000.0 | 是 |
| 藥品 | 國立成功大學醫學院附設醫院 | 112/12/28 | 否 | |
| 藥品計82項(含子項次計88項)(開口契約)(本次招標54項) | 高雄榮民總醫院 | 112/12/12 | 是 | |
| 藥品 | 國立成功大學醫學院附設醫院 | 112/11/23 | 2611200.0 | 是 |
| 8項骨科衛材單價開口契約 | 國立陽明交通大學附設醫院 | 112/11/09 | 5850000.0 | 是 |
| Minocycline Lyo inj 100mg單價開口契約 | 臺北榮民總醫院 | 112/10/12 | 是 | |
| 113-114年藥品單價開口契約 | 臺北榮民總醫院 | 112/09/15 | 是 | |
| 人體組織物等12項醫療器材採購案 | 國防部軍醫局 | 112/08/08 | 1152000.0 | 是 |
| 自體軟骨修補系統組等九項兩年開口契約 | 臺北榮民總醫院 | 112/01/04 | 5655000.0 | 是 |
| 藥品 | 國立成功大學醫學院附設醫院 | 111/11/09 | 1210000.0 | 是 |
| 衛材招標案 | 國立成功大學醫學院附設醫院 | 111/07/20 | 6810000.0 | 是 |
| 第62次藥委會通過新藥12項限制性招標案 | 臺北市立聯合醫院 | 111/05/18 | 是 | |
| 一次性自體軟骨修補系統組等2項 | 國防部軍醫局 | 111/02/23 | 4662000.0 | 是 |
| Minocycline Lyo inj 100mg單價開口契約 | 臺北榮民總醫院 | 111/02/22 | 是 | |
| 藥品 | 國立成功大學醫學院附設醫院 | 110/11/26 | 否 | |
| 藥品428項(含子項次計483項)(開口契約) | 高雄榮民總醫院 | 110/11/01 | 是 | |
| 49項常備藥品單價開口契約 | 國立陽明交通大學附設醫院 | 110/10/25 | 280000.0 | 是 |
| 臺中榮民總醫院111-112年藥品單價開口契約 | 臺中榮民總醫院 | 110/10/22 | 是 | |
| 惠立妥膜衣錠(或同等品)等4項 | 國防醫學院 | 110/07/21 | 8355780.0 | 是 |
| 藥品 | 國立成功大學醫學院附設醫院 | 110/03/23 | 1100000.0 | 是 |
| 藥品34項(開口契約)(本次招標16項) | 高雄榮民總醫院 | 109/12/24 | 是 |
